1. Show article details.

    BRIEF-Synergy pharmaceuticals announces resignation of CFO

    Reuters – 7:23 PM ET 04/27/2016

    Synergy Pharmaceuticals Inc (SGYP) : * Synergy Pharmaceuticals (SGYP) announces resignation of chief financial officer. * Says CFO Gary L. Sender resigned. * Bernard F. Denoyerwill assume responsibilities as principal financial officer Source text for Eikon: Further company coverage:

  2. Show article details.

    Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer

    Business Wire – 4:30 PM ET 04/27/2016

    Synergy Pharmaceuticals Inc. (SGYP) today announced that Gary L. Sender has resigned as the company’s Chief Financial Officer for personal reasons, effective April 30, 2016. “We thank Gary Sender for all of his contributions to Synergy and wish him all the best in his future endeavors,” said Gary S. Jacob, Chairman and CEO of Synergy Pharmaceuticals.

  3. Show article details.

    Synergy Pharmaceuticals to Present at the Deutsche Bank Health Care Conference

    Business Wire – 6:00 AM ET 04/26/2016

    Synergy Pharmaceuticals Inc. (SGYP) today announced the company is scheduled to present a corporate update at the 41st Annual Deutsche Bank Health Care Conference on Wednesday, May 4, 2016 at 2:50 p.m. Eastern Time.

  4. Show article details.

    BRIEF-Synergy Pharmaceuticals CEO Gary Jacob's 2015 total compensation $4.2 mln - SEC filing

    Reuters – 7:18 AM ET 04/20/2016

    Synergy Pharmaceuticals Inc (SGYP) : * Says CEO Gary Jacob's 2015 total compensation was $4.2 million versus $3.1 million in 2014 - SEC filing Source text http://1.usa.gov/1TiKxWI Further company coverage:

  5. Show article details.

    BRIEF-Synergy pharmaceuticals says FDA set Jan 29, 2017 as PDUFA for constipation drug

    Reuters – 7:10 AM ET 04/19/2016

    Synergy Pharmaceuticals (SGYP). * Synergy Pharmaceuticals (SGYP) announces acceptance of new drug application for plecanatide, a novel uroguanylin analog, in chronic idiopathic constipation. * Blind placebo-controlled phase 3 trials, one open-label long term safety study. * Fda prescription drug user fee act target action date is january 29, 2017.

  6. Show article details.

    Synergy Pharmaceuticals Announces Acceptance of New Drug Application for Plecanatide, a Novel Uroguanylin Analog, in Chronic Idiopathic Constipation

    Business Wire – 6:00 AM ET 04/19/2016

    PDUFA target action date of January 29, 2017 Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, today announced the U.S. Food and Drug Administration has determined that the company’s New Drug Application for plecanatide, its first uroguanylin analog, for the treatment of chronic idiopathic constipation...

  7. Show article details.

    Auditor warnings on large company solvency reach highest level since crisis

    MarketWatch – 11:53 AM ET 04/13/2016

    Auditors have made more warnings about the possibility their big clients may not survive than at any time since the financial crisis, according to Securities and Exchange Commission filings. Company annual report filings with the SEC for 2015 show the highest number of auditor going-concern warnings for large companies since 2008, the height of the financial crisis, according to Audit Analytics. A going-concern warning-- where auditors signal there is reasonable doubt the...

  8. Show article details.

    Synergy Pharmaceuticals Announces Closing of Convertible Notes Exchanges

    Business Wire – 4:30 PM ET 03/28/2016

    Synergy Pharmaceuticals Inc. (SGYP) today announced that it has closed separate, privately-negotiated exchanges with Eligible Holders of its outstanding 7.50% Convertible Senior Notes due 2019 for the consideration set forth below.

  9. Show article details.

    Synergy Pharmaceuticals’ Exchange Agreements to Reduce 50% of Senior Notes Outstanding

    Business Wire – 6:00 AM ET 03/21/2016

    Synergy Pharmaceuticals Inc. (SGYP) today announced that the exchange agreements entered into on March 17, 2016, with certain holders of $79.8 million aggregate principal amount of its Convertible Senior Notes due 2019, carrying a conversion price of $3.11 per share, will reduce Notes outstanding by 50% and the company will realize cash savings of approximately $24 million over the life of the Notes, ...

  10. Show article details.

    Synergy Pharmaceuticals Appoints Marino Garcia as Chief Strategy Officer

    Business Wire – 6:00 AM ET 03/10/2016

    Synergy Pharmaceuticals Inc. (SGYP) today announced the appointment of Marino Garcia to the newly created role of Executive Vice President and Chief Strategy Officer, effective immediately. This Smart News Release features multimedia.

  11. Show article details.

    Synergy Pharmaceuticals to Present at the 28th Annual ROTH Conference

    Business Wire – 6:00 AM ET 03/08/2016

    Synergy Pharmaceuticals Inc. (SGYP) today announced the company is scheduled to present a corporate update at the 28th Annual ROTH Conference on Monday, March 14, 2016 at 10:30 a.m. A live webcast of the presentation will be accessible through the Investor Relations section of the company’s website at www.synergypharma.com. About Synergy Pharmaceuticals Inc. Synergy is a biopharmaceutical company focu...

  12. Show article details.

    Synergy Pharmaceuticals Reports 2015 Fourth Quarter, Full-Year Financial Results and Business Update

    Business Wire – 5:15 PM ET 02/25/2016

    Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, today reported its financial results and business update for the fourth quarter and the year ended December 31, 2015.

  13. Show article details.

    BIND Therapeutics and Synergy Pharmaceuticals Announce Collaboration to Develop ACCURINS® with Proprietary Uroguanylin Analogs for Targeting Gastrointestinal Receptors on Tumors

    Business Wire – 8:00 AM ET 02/16/2016

    BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, and Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company pioneering the development of uroguanylin analogs as potential new treatments for functional gastrointestinal disorders and inflammatory bowel disease, today announced they have entered into a research co...

Page:

Today's and Upcoming Events

  • May
    9

    SGYP to announce Q1 earnings After Market (Unconfirmed)

  • Jun
    7

    Shareholders Meeting

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2016

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.